Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03744182 · ClinicalTrials.gov registry record · Phase 1
A Study of Multiple Doses of HM15211(Efocipegtrutide) in Obese Subjects With NAFLD
A Phase 1 study, sponsored by Hanmi Pharmaceutical Company Limited.
- Completed
- Registry status
- Phase 1
- Development phase
- 66
- Enrollment target
NCT03744182: Completed Phase 1 study, sponsored by Hanmi Pharmaceutical Company Limited.
NCT03744182 is a Phase 1 study that has completed, run by Hanmi Pharmaceutical Company Limited. The registered enrollment target is 66 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (10% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03744182, a Phase 1 study, has completed, sponsored by Hanmi Pharmaceutical Company Limited.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 66 participants
- Enrollment target
Study Summary
This study is a phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple doses of HM15211 in obese subjects with NAFLD
Primary Outcome
Cardiovascular events, rash/inflammatory dermatitis and other skin disorders, GI events, and gallstone formation \[cholelithiasis\] were managed following a separate AE guidance document
Interventions
- DRUG HM15211
- DRUG Placebo of HM15211
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2018-11-01 |
| Est. Completion | 2020-03-18 |
| Phase | Phase 1 |
What the finished NCT03744182 record still lists
NCT03744182 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 66 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (10% higher).
The record links to 0 conditions, and to 2 interventions - of which HM15211 is the first listed.
NCT03744182 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03744182 about?
NCT03744182 is a clinical study titled "A Study of Multiple Doses of HM15211(Efocipegtrutide) in Obese Subjects With NAFLD". This study is a phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple doses of HM15211 in obese subjects with NAFLD
What is the current status of trial NCT03744182?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 66 participants. The study started on 2018-11-01. Estimated completion is 2020-03-18.
What interventions are being tested in trial NCT03744182?
The interventions under investigation include: HM15211 (DRUG), Placebo of HM15211 (DRUG).
Who is sponsoring clinical trial NCT03744182?
This trial is sponsored by Hanmi Pharmaceutical Company Limited, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03744182's enrollment target sits among peer trials
66 786th of 2000 higher than 1,203 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02584244 · 66 participants · Phase 1
Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
- NCT03067051 · 66 participants · Phase 1
Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System
- NCT03754725 · 66 participants · Phase 1
Ferritin and Iron Burden in SAH sIRB
- NCT03875378 · 66 participants · Phase 2
Transdermal Estrogen in Women With Anorexia Nervosa
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI